CervoMed advances 100 mg twice-daily neflamapimod regimen after FDA exposure-limit removal
AI Summary- CervoMed announced a 50 mg tablet, FDA limit removal and manufacturing advances for neflamapimod.
- 100 mg twice-daily dosing is modeled to increase trough concentrations approximately 33% versus 40 mg three-times-daily dosing.
- 39-week dog toxicology established a NOAEL more than 30-fold above prior active exposure levels.